The results are expected to be presented at the end of the second quarter of 2021 and will, together with previously completed phase 1 studies, form the basis for a global phase 2 programme that is planned to start in the autumn.
“The phase 1b study of ROSgard is the last part of a comprehensive phase 1 programme and the investigational drug will now be evaluated in the primary target group for treatment for the first time. Preparations for our planned global phase 2 programme are going well and we look forward to initiating this in the autumn,” Guard Therapeutics’ CEO,
The investigational drug, ROSgard, has the ability to counteract severe oxidative stress – a common denominator for many different types of acute kidney injury. In the initial clinical development phase,
© Modular Finance, source